Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines

被引：28

作者：

Edwards, Morven S. ^{[1
]}

Lane, Heidi J. ^{[1
]}

Hillier, Sharon L. ^{[2
,3
,4
,5
]}

Rench, Marcia A. ^{[1
]}

Baker, Carol J. ^{[1
,6
]}

机构：

[1] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[2] Univ Pittsburgh, Sch Med, Dept Obstet, Pittsburgh, PA USA

[3] Univ Pittsburgh, Sch Med, Dept Gynecol, Pittsburgh, PA USA

[4] Univ Pittsburgh, Sch Med, Dept Reprod Sci, Pittsburgh, PA USA

[5] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA USA

[6] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA

来源：

VACCINE | 2012年 / 30卷 / 28期

基金：

美国国家卫生研究院;

关键词：

Group B Streptococcus; Vaccine; Antibody; Glycoconjugate; Polysaccharide; Durability; TOXOID CONJUGATE VACCINE; PREGNANT-WOMEN; DISEASE; ADULTS; IMMUNOGENICITY; INFECTION; SAFETY; LEVEL; IA;

D O I：

10.1016/j.vaccine.2012.04.048

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The duration of functional activity of group B streptococcal (CBS) glycoconjugate vaccine-induced capsular polysaccharide-specific (CPS) IgG was evaluated among healthy adult responders. Opsonophagocytic activity declined significantly from a 4-week post-immunization peak, but substantial functional activity, exceeding 1 log(10) reduction in CBS cfu/mL, was retained at 18 months to 2 years post-immunization for each CBS type assessed. The persistence of functional antibody activity when CBS CPS-specific IgG concentrations decline, although remaining significantly higher than pre-immunization levels, suggests that long-term protection may be expected from candidate CBS glycoconjugates administered to this population. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：4123 / 4126

页数：4

共 22 条

[1]

[Anonymous], 2012, ACT BACT COR SURV RE

[2] Pneumococcal vaccination and revaccination of older adults [J].

Artz, AS ;

Ershler, WB ;

Longo, DL .

CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (02) :308-+

[3] Dose-response to type V group B streptococcal poly saccharide-tetanus toxoid conjugate vaccine in healthy adults [J].

Baker, Carol J. ;

Rench, Marcia A. ;

Paoletti, Lawrence C. ;

Edwards, Morven S. .

VACCINE, 2007, 25 (01) :55-63

[4] QUANTITATIVE-DETERMINATION OF ANTIBODY TO CAPSULAR POLYSACCHARIDE IN INFECTION WITH TYPE-3 STRAINS OF GROUP-B STREPTOCOCCUS [J].

BAKER, CJ ;

KASPER, DL ;

TAGER, IB ;

PAREDES, A ;

ALPERT, S ;

MCCORMACK, WM ;

GOROFF, D .

JOURNAL OF CLINICAL INVESTIGATION, 1977, 59 (05) :810-818

[5] Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].

Baker, CJ ;

Paoletti, LC ;

Wessels, MR ;

Guttormsen, HK ;

Rench, MA ;

Hickman, ME ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150

[6] Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines [J].

Baker, CJ ;

Paoletti, LC ;

Rench, MA ;

Guttormsen, HK ;

Edwards, MS ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) :1103-1112

[7] Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine [J].

Baker, CJ ;

Rench, MA ;

McInnes, P .

VACCINE, 2003, 21 (24) :3468-3472

[8] Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III [J].

Baker, CJ ;

Rench, MA ;

Fernandez, M ;

Paoletti, LC ;

Kasper, DL ;

Edwards, MS .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) :66-73

[9] CORRELATION OF MATERNAL ANTIBODY DEFICIENCY WITH SUSCEPTIBILITY TO NEONATAL GROUP-B STREPTOCOCCAL INFECTION [J].

BAKER, CJ ;

KASPER, DL .

NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) :753-756

[10] Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery [J].

Campbell, JR ;

Hillier, SL ;

Krohn, MA ;

Ferrieri, P ;

Zaleznik, DF ;

Baker, CJ .

OBSTETRICS AND GYNECOLOGY, 2000, 96 (04) :498-503

← 1 2 3 →